Identifying Biomarkers to Select Patients with Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BRPC, LAPC) for Radiotherapy (RT)

Authors

Grace L. Waterman, The University of Texas MD Anderson Cancer CenterFollow
Galia Jacobson, The University of Texas MD Anderson Cancer Center
Connor Thunshelle, The University of Texas MD Anderson Cancer Center
Eugene J. Koay MD, PhD, The University of Texas MD Anderson Cancer Center

Files

Keywords

Pancreatic Ductal Adenocarcinoma, Radiotherapy, Biomarkers, CA19-9, Lymphopenia

Program Affiliation

Summer Undergraduate Research Program

Recommended Citation

Waterman, Grace L.; Jacobson, Galia; Thunshelle, Connor; and Koay, Eugene J. MD, PhD, "Identifying Biomarkers to Select Patients with Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BRPC, LAPC) for Radiotherapy (RT)" (2022). Summer Experience 2022. 34.
https://openworks.mdanderson.org/sumexp22/34